SRSF6

Across TCGA pan-cancer cohorts, SRSF6 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SRSF6’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where SRSF6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SRSF6 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

PDAC, LSCC, and LUAD are the cancer types where SRSF6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SRSF6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	−1.018	<.001	7	view →
LSCC	All	II,III,IV	+0.763	.003	4	view →
LUAD	All	All	+0.704	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SRSF6–PDAC

Open the PDAC breakdown →